NeOnc gets FDA written feedback backing NEO212 CMC plan, flags bioavailability study for tablet switch

NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc.

NTHI

0.00
  • NeOnc received FDA written feedback on CMC plans for NEO212, supporting continued development and setting conditions for late-stage work.
  • Company canceled its July 9, 2026 Type B End-of-Phase 1 meeting after FDA said written responses could serve as the official record.
  • FDA flagged an in vivo relative bioavailability study to support the planned switch from capsules to tablets.
  • FDA outlined CMC steps needed before tablets enter a confirmatory phase, including final formulation and at least one GMP batch.
  • NeOnc is assessing timelines and costs, with an updated development plan expected following the review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150900PRIMZONEFULLFEED9762402) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.